Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Current Assets (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Current Assets for 15 consecutive years, with $76.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Assets rose 20.92% to $76.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $76.2 million, a N/A change, with the full-year FY2025 number at $79.2 million, up 27.93% from a year prior.
  • Current Assets was $76.2 million for Q4 2025 at Aytu Biopharma, down from $81.1 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $105.2 million in Q2 2021 to a low of $59.9 million in Q2 2022.
  • A 5-year average of $74.9 million and a median of $72.8 million in 2023 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: skyrocketed 39.53% in 2021, then crashed 43.05% in 2022.
  • Aytu Biopharma's Current Assets stood at $87.5 million in 2021, then dropped by 19.3% to $70.6 million in 2022, then grew by 1.08% to $71.4 million in 2023, then fell by 11.65% to $63.1 million in 2024, then rose by 20.92% to $76.2 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Current Assets are $76.2 million (Q4 2025), $81.1 million (Q3 2025), and $79.2 million (Q2 2025).